TrialAmerican journal of respiratory and critical care medicine2026

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.

Ryo Okuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.